Estrogen receptor alpha regulates the expression of adipogenic genes genetically and epigenetically in rat bone marrow-derived mesenchymal stem cells

Ceylan V. Bitirim¹, Zeynep B. Ozer¹ and Kamil C. Akcali¹,²

¹ Stem Cell Institute, Ankara University, Ankara, Turkey
² Department of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey

ABSTRACT

Regulation of the efficacy of epigenetic modifiers is regarded as an important control mechanism in the determination and differentiation of stem cell fate. Studies are showing that the effect of estrogen is important in the differentiation of mesenchymal stem cells (MSCs) into adipocytes, osteocytes, and chondrocytes. Activation of certain transcription factors and epigenetic modifications in related genes play an active role in the initiation and completion of adipogenic differentiation. Understanding the role of estrogen in diseases such as obesity, which increases with the onset of menopause, will pave the way for more effective use of estrogen as a therapeutic option. Demonstration of the differentiation tendencies of MSCs change in the presence/absence of estrogen, especially the evaluation of reversible epigenetic changes, will provide valuable information for clinical applications. In this study, the effect of estrogen on the expression of genes involved in adipogenic differentiation of MSCs and accompanying epigenetic modifications was investigated. Our results showed that estrogen affects the expression of adipogenesis-related transcription factors such as PPARγ, C/EBPα and Adipsin. In addition, after estrogen treatment, increased accumulation of estrogen receptor alpha (ERα) and repressive epigenetic markers such as H3K27me2 and H3K27me3 were observed on the promoter of given transcription factors. By using co-immunoprecipitation experiments we were also able to show that ERα physically interacts with the zeste homolog 2 (EZH2) H3K27 methyltransferase in MSCs. We propose that the increase of H3K27me2 and H3K27me3 markers on adipogenic genes upon estrogen treatment may be mediated by the direct interaction of ERα and EZH2. Taken together, these findings suggest that estrogen has a role as an epigenetic switcher in the regulation of H3K27 methylation leading to suppression of adipogenic differentiation of MSC.

INTRODUCTION

Mesenchymal stem cells (MSC) are adult stem cells and give rise to adipocytes, osteocytes, and chondrocytes. They tend to differentiate into one cell line while suppressing...
differentiation into another cell type (Jeong & Yoon, 2011). Due to their wide-range differentiation capacity, MSCs are widely used in clinical and preclinical studies. After menopause, the decrease in circulating estrogen causes an increase in adipose tissue (Heim et al., 2004; Heine et al., 2000; Stubbins et al., 2012; Jeong & Yoon, 2011). Moreover, estrogen replacement therapy can reverse the enhanced fatty acid formation resulted from estrogen deficiency in postmenopausal women (Jeong & Yoon, 2007; Carani et al., 1997).

Adipogenesis is a well-orchestrated and complex multistep physiological process that requires molecularly sequential regulation of transcription factors such as CCAAT/enhancer-binding protein alpha (C/EBPα), PPAR-γ, and Adipsin. Among these factors, PPAR-γ and C/EBPα are key regulators. Through RNA sequencing, it was demonstrated that co-expression of PPARγ and C/EBPα leads to synergistic activation of many key metabolic adipocyte genes (Madsen et al., 2014; Tang, Zhang & Daniel Lane, 2004; Musri et al., 2010; Zuo, Qiang & Farmer, 2006). In particular, PPARγ plays a dominant role in this process (Meyer et al., 2016). Adipsin, which is also regulated by PPARγ, is regarded as a late marker of adipocyte differentiation. Importantly, adipsin deficiency directly modulates BMSC fate by hindering their differentiation into adipocytes (Aaron et al., 2021). Expression of early and late adipogenic differentiation markers in MSCs can be inhibited by treatment of both estrogen and phytoestrogen (Evans, Barish & Wang, 2004; Kim et al., 2009). There is an inverse correlation between osteogenesis, chondrogenesis, and adipogenesis in MSCs (Hong et al., 2011; Zhao et al., 2011; Okazaki et al., 2002). Estrogen plays an important role in the reciprocal control of adipogenic and osteogenic differentiation in progenitor cells (Chen et al., 2016; Dang & Löwik, 2004; Foryst-Ludwig et al., 2008; Jeong & Yoon, 2011; Hong, Colpan & Peptan, 2006). The observation of an increase in body fat percentage and the incidence of obesity with menopause and ageing has been attributed to deregulation in progenitor cell differentiation. This may explain the clinical effects of decreased circulating estrogen, however, the molecular and epigenetic mechanisms related to this effect are still elusive.

ERα and ERβ work with epigenetic mediators such as histone acetyltransferases (HATs), histone deacetylase (HDACs), and SWI/SNF complexes, enabling estrogen to play a role in epigenetic regulation of the transcription of target genes. (Hong et al., 2011; Zhao et al., 2011; Stossi, Madak-erdogan & Benita, 2009; Zubairy & Oesterreich, 2005). Estrogen both repress and stimulate the gene expression through estrogen receptors. Epigenetic mediators, zeste homolog 2 (EZH2) and histone deacetylase 9c (HDAC9c) have been shown to play a role in the regulation of age-related osteogenic and adipogenic differentiation processes in MSCs (Chen et al., 2016; Chen et al., 2011). EZH2 is considered one of the key epigenetic regulators in development and cell differentiation. EZH2 is one of the core subunits of polycomb repressive complex 2 (PRC2) and catalyzes mono-, di-, and trimethylation of histone three lysine 27 (H3K27), which are epigenetic hallmarks of repressed chromatin (Mu et al., 2018). Similar to estrogen, previous studies demonstrated that EZH2 plays an important role in the regulation of MSC differentiation. It has been reported that EZH2 has a pivotal role in the adipogenic lineage commitment of MSCs in an age-dependent manner (Chen et al., 2016). Genome-wide profiling studies have revealed that EZH2 may act as a molecular switcher to adjust the balance between osteogenic and adipogenic differentiation in MSCs (Hemming et al., 2016;
However, the role of EZH2 in the molecular mechanism of the coordination of the adipogenic differentiation and the estrogen-mediated epigenetic control in MSC differentiation is not elucidated. Here, we aimed to further elucidate the association between estrogen and epigenetic modifications including histone and DNA methylation which underlie the regulation of MSC differentiation into adipocytes. We propose that the physical interaction between EZH2 and ERα in the presence of estrogen may be the epigenetic mechanism underlying the transcriptional suppression of key adipogenic genes such as PPARγ, C/EBPα and Adipsin. Our data support that estrogen inhibits adipogenesis by forming a co-repressor complex that acts on adipogenic genes with epigenetic regulators.

MATERIALS & METHODS

Animal preparation and cell culture
Heterogeneous bone marrow cells were isolated from the tibia and femur of ten normal females and ten ovariectomized 9-week-old, 280–300 g Sprague–Dawley rats. Ovariectomy procedure was performed to mimic the post-menopausal stage. The ovariectomy procedure was performed under full anaesthesia using ketamine at a concentration of 30 mg/kg. Almost after 2 months after the operation, the ovariectomized animals were used for experiments to ensure the total deficiency of estrogen. The animals that were showing signs of sickness and lost more than 20% weight after the operation were excluded. The animals were always kept and permitted unlimited access to food and water. The animals express their normal behavioural patterns, since they have sufficient space and proper facilities. The behavioural and physiological changes of ovariectomized animals were monitored daily by the veterinarian. They were housed under controlled environmental conditions in the animal holding facility of the Department of Molecular Biology and Genetics at the İhsan Doğramacı Bilkent University (Ankara, Turkey). The experimental protocol is arranged with İhsan Doğramacı Bilkent University’s guidelines on humane care and the use of laboratory animals. All experimental protocols were approved by the Laboratory Animal Welfare and Ethics Committee of Bilkent University. Permission number for using animals: 2009/18.

After sacriﬁcation, bone marrow cells were ﬂushed with a ﬁve mL syringe in DMEM (HyClone, Logan, UT, USA) containing 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 1% penicillin-streptomycin antibiotic (HyClone, Logan, UT, USA) after cervical dislocation. The bone marrow cells were cultured in MesenCult medium (Stem Cell Technologies, Vancouver, Canada) including 20% supplement (Stem Cell Technologies, Vancouver, Canada) and 1% penicillin-streptomycin solution (HyClone, Logan, UT, USA) for 14 days. After washing with sterile 1XPBS the media were changed every 4 days. In addition to the untreated control group, the cells were treated $10^{-7}$ M estrogen (17ß-estradiol, Sigma, Schnelldorf, Germany) and $10^{-6}$ M tamoxifen (Sigma, Schnelldorf, Germany) from the 1st day of culture until the 14th day to obtain the estrogen-treated and tamoxifen-treated groups.
Quantitative RT-PCR

Total RNA isolation from MSCs at the end of the 14th day of the cell culture was performed using Nucleospin RNA II kit isolation kit (Macherey-Nagel, Düren, Germany) according to instructions of the manufacturer. For cDNA synthesis, one μg of RNA was used for each reaction. cDNA synthesis was performed using DyNAmo cDNA synthesis kit (Finnzymes, Espoo, Finland). cDNA was amplified by SYBR green real-time PCR kit (Finnzymes, Espoo, Finland). Expression of transcription factor genes was normalized according to cyclophilin expression level. Fold changes in the expression of the genes were analyzed based on the comparative ($2^{-ΔΔCt}$) method. As a calibrator, the normal female MSC group was used. The primer sequences used in this study are listed in Table 1.

Co-Immunoprecipitation (Co-IP) assay and western blotting

MSCs were scraped from cell culture flasks in ten ml 1XPBS with a scraper. The cell suspension was centrifuged at 900 $\times$ g for 5 min at 4 °C. The pellet was dissolved in lysis buffer and incubated on ice for 30 min by finger tipping every 5 min. Then, the lysates were centrifuged at 12,000 $\times$ g for 20 min at 4 °C. The supernatant containing total proteins was taken and stored at −80 °C. The protein concentration was determined by performing BCA assay (Thermo, Rockford, IL, USA). Protein lysates were immunoprecipitated using anti-ERα (cat.no: sc-8002; Santa Cruz, CA, USA), monoclonal antibody and IgG (cat.no: sc-2025; Santa Cruz, CA, USA) monoclonal antibody as a negative control. Precipitation was performed using protein G magnetic beads of Co-IP kit (cat.no: 88847; Thermo, Rockford, IL USA) and the procedure was performed according to the manufacturer’s protocol. The protein lysates were separated by 10% SDS-PAGE and transferred to a polyvinylidene fluoride membrane. The membranes were blocked in 5% BSA in 0.1% TBS-T. Immunoblotting was performed using the monoclonal antibody against EZH2 (cat.no: 5246; 1:500; Cell Signaling, Danvers, MA, USA) monoclonal antibody as a negative control. The secondary antibody solution at the concentration for overnight and 4 °C. The membranes were incubated in antibody solution at the concentration for overnight and 4 °C. The secondary antibody anti-Rabbit-HRP (cat.no: 7074; 1:5,000; Cell Signaling, Danvers, MA, USA) was applied for 1 h in blocking solution. Finally, Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Waltham, IL, USA) was used for

| Genes      | Sequence                     | Product length |
|------------|------------------------------|----------------|
| C/EBPα     | Forward: 5′-AGTCGGTGGAATAAGAACAGC-3′ | 138            |
|            | Reverse: 5′-CATTCGCACGTTCACTCC-3′     |                |
| PPARγ      | Forward: 5′-TETTCAAGGTAGCCCTGTTTGC-3′ | 198            |
|            | Reverse: 5′-AATCTGAGCCCTCTGAGAT-3′     |                |
| Adipsin    | Forward: 5′-TTGTTAGAGAAGCAGGTGGT-3′  | 110            |
|            | Reverse: 5′-AGGGTCCAGAGACTGGACAGG-3′   |                |
| RUNX2      | Forward: 5′-TAACGCTTCTCAAAATCTC-3′  | 115            |
|            | Reverse: 5′-GGCAGTCAGAGACAATAAATA-3′   |                |
| Cyclophilin| Forward: 5′-GGGAAGGGGAAAAGGGGACAT-3′ | 211            |
|            | Reverse: 5′-GAGGCAGAGATTACAGGGG-3′     |                |
chemiluminescence detection. The membranes were visualized by ChemiDoc gel imaging system (Bio-Rad, Hercules, CA, USA).

**Chromatin Immunoprecipitation (ChIP) assay**

Simple-ChIP Enzymatic Chromatin IP Kit (Agarose Beads) (Cell Signaling Technology, Danvers, MA, USA) was used for ChIP assay according to the manufacturer’s protocol. MSCs were incubated with or without either estrogen. A total of 9 μg of chromatin DNA was immunoprecipitated using anti-ERα (cat.no: sc-8002; Santa Cruz, CA, USA), monoclonal antibody, anti-H3K27me2 monoclonal antibody (cat.no: 9728; Cell Signaling, Danvers, MA, USA), and anti-H3K27me3 monoclonal antibody (cat.no: 9733; Cell Signaling, Danvers, MA, USA) at 1:50 dilution rate. IgG (cat.no: sc-2025; Santa Cruz, CA, USA) monoclonal antibody was used as a negative control. A total of 10% of DNA was used as input. ChIP assay was analyzed with quantitative PCR using qPCR 2X Master mix (Ampliqon, Denmark) and results were expressed using the percent input method: Percent input = (Primer Efficiency) ^ (CT input – CT IP sample) / Percentage of input. qPCR conditions were 95 °C for 15 min, 95 °C for 30 s, 60 °C for 1 min, 72 °C for 1 min and 30 cycles, 72 °C for 10 min.

**Bisulfite sequencing**

DNA methylation status on the promoter of PPARγ and C/EBPα genes was analyzed by bisulfite sequencing. Either DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD, USA) or NucleoSpin Tissue kit (Machery-Nagel, Düren, Germany) was used for DNA purification following the manufacturer’s instructions. 350 ng of DNA was used for each bisulfite conversion reaction performed using EpiTech Bisulfite Kit (Qiagen, Germantown, MD, USA). Amplification of converted DNA was performed by HotstarTaq polymerase (Qiagen, Germantown, MD, USA). Bisulfite-specific primers were created using MethPrimer software (*Li & Dahiya, 2002*) for PPARγ and C/EBPα. ERα primers were designed as given previously (*Zama & Uzumcu, 2009*). The primer sequences used in bisulfite sequencing experiments are listed in Table 2. PCR products were extracted from 1% agarose gel using QIAquick Gel Extraction Kit (Qiagen, Germantown, MD, USA) and cloned into DH5α bacteria cells by TA Cloning (pGEM-T Easy Vector system, Promega, Madison, WI, USA). Plasmid DNA was isolated by using Plasmid Mini Kit (Qiagen, Germantown, MD, USA) and clones were sequenced by commercial services (İONTÈK, Ankara, Turkey; DONE Genetics, Ankara, Turkey).

| Genes  | Sequence                  | Product length |
|--------|---------------------------|----------------|
| C/EBPα | Forward 5’TGGGTGTATATTAGGTTTTTTGT-3’ | 167            |
|        | Reverse 5’-AACCCCTATCCATCCTTAA-3’ |                |
| PPARγ  | Forward 5’TTTTAGGTTTTTTAGAAGTGTTT-3’ | 368            |
|        | Reverse 5’TCCATAACCCCTAACCTACTC-3’ |                |
Statistical analysis
The statistical significance between the groups of qRT-PCR and western blotting experiments were determined by the unpaired Student’s t-test. The values from qRT-PCR were expressed as the means ± SD (N = 6) and from ChIP-qPCR were expressed as the means ± SD (N = 3) and the measurements from western blotting were expressed as the means ± SD (N = 3). p < 0.05 was chosen statistically significant. N number indicated the number of rats each of which was used as single donor.

RESULTS
Transcriptional repression of adipogenic genes upon estrogen treatment in MSC
To determine whether the expression of adipogenic genes changes in the presence of estrogen, we first analyzed the transcription levels of key adipogenic genes; PPARγ, C/EBPα, and Adipsin in MSCs isolated from normal females (female) and ovariectomized rats (ovex). MSCs were incubated for 14 days in the presence and absence of estrogen. Previously, the inhibitory effect of estrogen on the expression of adipogenic differentiation markers in MSCs was reported (Zhao et al., 2011). According to our results, estrogen treatment caused significant downregulation of PPARγ (Fig. 1A), C/EBPα (Fig. 1B) and Adipsin (Fig. 1C) in MSC obtained from both normal female and ovex rat. In addition to this, estrogen deficiency results in increased mRNA expression of PPARγ, C/EBPα, and Adipsin. The transcript levels of the major regulators of adipogenesis are significantly higher in ovex-MSCs compared to normal female-MSCs, suggesting that estrogen deficiency may associate with the adipogenic commitment of MSCs.

Physical interaction of ERα with EZH2
To address the epigenetic mechanism underlying the suppressive effect of estrogen on the adipogenic genes, firstly we investigate the functional link between ERα and EZH2 and analyzed whether the two proteins could interact. EZH2 catalyzes methylation of H3K27 which is a histone modification associated with gene repression. To address this issue, the co-IP assay was performed. The MSCs isolated from normal female and ovex animals were incubated with estrogen. Immunoprecipitation was performed in the MSC protein extract using ERα antibody followed by blotting with anti-EZH2 antibody. The direct interaction between ERα and EZH2 both in normal and ovex MSC was indicated (Fig. 2). Notably, the ERα-EZH2 interaction tends to be induced strongly upon estrogen treatment in ovex group. In the light of these observations, we strongly suggest that estrogen-dependent adipogenic gene regulation might occur through the direct interaction of ERα with EZH2 to mediate the H3K27 methylation on the promoter of adipogenic genes. Moreover, estrogen administration may possess a much stronger effect on gene expression and differentiation in ovex-MSCs than normal female-MSCs.
Binding of ERα and methylated H3K27 on adipogenic genes upon estrogen treatment

After indicating the direct interaction between ERα and EZH2, to further understand the cross-talk between ERα and histone modifications, we next examined whether ERα
regulates the methylation status of H3K27 in an estrogen-dependent manner. To test this possibility, we performed a conventional ChIP-qPCR assay to analyze the binding status of ERα, H3K27me2, and H3K27me3 on PPARγ, C/EBPα, and Adipsin genes. In ChIP assay, Tamoxifen was also used as an antagonist to ERα to validate the effect of estrogen on binding of ERα and methylated H3K27. MSCs isolated from normal female and ovex rats were incubated either with estrogen or tamoxifen. We have shown that estrogen treatment induces almost three fold in the binding of ERα on PPARγ gene, and almost tenfold on C/EBPα in MSCs isolated from both normal (Fig. 3A) and ovex rat (Fig. 3B). In particular, estrogen treatment stimulated the binding of ERα to Adipsin almost ten fold in female group and 25 fold in ovex group. This result suggests that ERα is directly involved in adipogenic gene expression via binding on PPARγ, C/EBPα, and Adipsin genes in MSCs. The enhancement in the occupancies of H3K27me2 and H3K27me3 after estrogen treatment on the adipogenic genes was also observed (Figs. 3C–3F). The existence of H3K27me2 induced by estrogen more than two fold on PPARγ and more than five fold on Adipsin both in female and ovex MSCs. The accumulation of H3K27me2 on C/EBPα was dramatically reached up to 40 fold in female and up to 20 fold

**Figure 3** Effects of estrogen on the accumulation of ERα and methylated histone proteins to the promoters of adipogenic transcription factor genes. The enrichment of (A, B) ERα, (C, D) H3K27me2 and (E, F) H3K27me3 on PPARγ, C/EBPα and Adipsin genes were analyzed by ChIP analysis. Genomic DNA extracted from normal female and ovex female rat MSCs which were cultured either estrogen or tamoxifen were immunoprecipitated with anti-ERα, anti-H3K27me2 and anti-H3K27me3. The alteration in the accumulation of these proteins on adipogenic genes was quantified by qPCR. The data were expressed as a percent of input. An asterisk (*) indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001. All data are represented as the mean ± SD (n = 3).
in ovex (Figs. 3C–3D). Similar to H3K27me2, estrogen treatment also increased the H3K27me3 binding more than three fold on PPARγ and more than five fold on C/EBPα and Adipsin genes (Figs. 3E–3F). Especially the accumulation level reached up to 20 fold on Adipsin and C/EBPα in female and ovex female rat. Tamoxifen treatment significantly decreased the enrichment of ERα, H3K27me2 and H3K27me3 on adipogenic genes in female groups (Figs. 3A–3E). On the other hand, in the ovex groups, we did not observe this significant reduction of H3K27me2 and H3K27me3 on C/EBPα and Adipsin genes (Figs. 3D–3F). Taken together, our data demonstrated that the downregulation of transcription of PPARγ, C/EBPα, and Adipsin may be correlated with the increased recruitment of H3K27me2 and H3K27me3 on the promoter regions.

**CpG methylation status in the promoter regions of adipogenic transcription factors**

In addition to histone methylation, we next tested the other major epigenetic modification, DNA methylation. CpG methylation of two master regulator genes; PPARγ and C/EBPα, in polyclonal cultures of MSCs, were analyzed by bisulfite DNA sequencing. PPARγ and C/EBPα are major contributors to the expression of adipogenesis-related gene Adipsin (Rosen et al., 2002). The distribution of CpG residues in each promoter region, which are given in Fig. 4A, was examined and the data were expressed as a percentage of CpG.
methylation for both PPARγ and C/EBPα (Fig. 4B). Despite some heterogeneity between clones, the level of CpG methylation at each gene was determined taking the average percentage of CpG methylation from 5–7 bacterial colonies. Although DNA hypermethylation on C/EBPα was significant upon estrogen in normal female-MSCs, PPARγ displayed not quite significantly higher average methylation in the estrogen-treated group compared to the untreated group in normal females. On the contrary, there were no significant differences observed within ovex groups. Notably, estrogen deficiency did not result in a significant change of DNA methylation status between ovex and normal female-MSCs.

**DISCUSSION**

Epigenetic mechanisms are reversible, which is why the identification of genetic and epigenetic mechanisms underlying reprogramming of key aspects of MSC such as cell fate determination may provide important insight for clinical applications in treatments of obesity (Ling & Rönn, 2019). Estrogen deficiency is considered a major cause of osteoporosis, osteoarthritis, and obesity in postmenopausal women (Palmisano, Zhu & Stafford, 2017; Evans, Barish & Wang, 2004; Zhao et al., 2008). Prior studies were demonstrated that estrogen represses adipogenesis by inhibiting the expression of early and late adipogenic differentiation markers while promoting osteogenesis in MSCs (Glenske et al., 2019; Takada et al., 2007; Ye et al., 2012; Sävendahl, 2005; Zhao et al., 2011; Zhang et al., 2012; Zhou et al., 2001). Moreover, the ChIP-seq analysis has shown that transitions of epigenetic marks, such as H3K9ac, H4K5ac, H3K4me1, H3K4me3, and H3K36me3 on transcription factors involved in MSC differentiation, such as Runx2, C/EBPβ, C/EBPα, PPARγ coordinate the cell fate decision of MSC (Meyer et al., 2016).

Here, we investigated how estrogen and ERα coordinate transcriptional regulation of adipogenic genes in MSCs both at the genetic and epigenetic levels.

PPARγ and C/EBPα lead to synergistic activation of many key metabolic adipocyte genes (Madsen et al., 2014). In particular, PPARγ plays a dominant role in this process. Due to these reasons, we have chosen PPARγ and C/EBPα as early and essential adipogenesis markers. In addition, late adipocyte marker Adipsin is also regulated by PPARγ and is essential for MSC differentiation (Aaron et al., 2021).

Our data revealed that estrogen downregulates mRNA expression of major adipogenic genes; PPARγ, C/EBPα, and Adipsin, while estrogen deficiency induces the expression of these genes in MSCs. Thus, estrogen treatment reverses this induced effect caused by a lack of estrogen suppressing gene transcription. These results agree with observations that report estrogen ERs dependent regulation of adipose tissue formation and decrease in body fat distribution via estrogen replacement in early postmenopausal women (Babaei et al., 2017; Pedersen et al., 1992; Dang & Löwik, 2004). Moreover, within the mesenchymal lineage, RUNX2 and PPARγ are major factors that are responsible for osteogenic and adipogenic differentiation, respectively (Meyer et al., 2016). To verify the specific effect of estrogen on adipogenic-related genes independently of other possible factors, we evaluated the expression level of osteoblast related gene Runx2. Our data demonstrated...
that estrogen treatment causes a significant increase in the expression of Runx2 while suppressing expression of adipogenesis related genes (Fig. S1).

To support our genetic data, we aimed to delineate the potential effects of estrogen hormone and ERα in the epigenetic regulation mechanisms which control the adipogenesis in MSCs. It suggests that many co-regulators and transcription factors possessing chromatin-modifying activities maintain epigenetic regulation during adipogenesis (Teven et al., 2011). The histone modifications play important role in changing chromatin architecture upon adipogenic differentiation.

According to previous studies, various histone modifications are crucial for chromatin reorganization and regulation of gene transcription during MSC adipogenic differentiation. The transcriptional control of PPARγ and CEBPα through the formation of H3K4/H3K9me3 bivalent domains in lineage-committed mesenchymal stem cells and preadipocytes was also established (Matsumura et al., 2015; Li et al., 2010). To establish the link between the presence of estrogen and the modulation of inactive histone proteins on adipogenic gene promoters, we firstly examined the binding status of ERα on these genes. ERα is a nuclear receptor and acts as a transcription factor. Co-activators and co-repressors are directly recruited by nuclear receptors as a consequence of ligand-binding (Liu, Zou & Qin, 2017; Stossi, Madak-erdogan & Benita, 2009; Shang et al., 2000). In contrast to the well-known stimulatory effect of estrogen, ligand-activated ERα also represses gene expression by recruiting co-repressor/histone deacetylase (HDAC) or histone methyltransferase-containing complexes (Stossi, Madak-erdogan & Benita, 2009). In this study, we reported the enhanced recruitment of ERα to the PPARγ, C/EBPα, and Adipsin upon estrogen treatment. ERα works highly dynamically as a nuclear receptor for a cohort of co-regulator complexes such as p160, p300, and CtBP1 and enzymatic complexes such as SWI/SNF, histone acetyltransferases (Shang et al., 2000; Senyuk, Sinha & Nucifora, 2005; Stossi, Madak-erdogan & Benita, 2009). Stossi and colleagues reported that ERα initiates transient stimulation of transcription and it uses p300 to recruit CtBP1-containing complexes. These complexes modulate chromatin modifications which lead to transcriptional repression at early estrogen-repressed genes (Stossi, Madak-erdogan & Benita, 2009). Like ERα binding to adipogenic genes, estrogen treatment dramatically induces enrichment of methylated H3K27 on the PPARγ, C/EBPα, and Adipsin in MSCs, indicating that binding of liganded-ERα on these promoters enhance methylation of H3K27. These findings support our qRT-PCR data suggesting that estrogen may suppress adipogenic gene expression through accumulation of methylated H3K27 proteins on the gene promoters. In addition, we have demonstrated that tamoxifen treatment drastically decreases the accumulation of ERα, H3K27me2 and H3K27me3 on PPARγ, C/EBPα and Adipsin which is in support of epigenetic repression is mediated by ERα signaling. On the other hand, we did not observe this significant reduction of H3K27me2 and H3K27me3 on C/EBPα and Adipsin genes in the ovex groups which lack estrogen. These results suggest that estrogen/ERα may function as an epigenetic switch for MSC adipogenic fate determination and modulate chromatin modifications coordinately.
Accumulated evidence highlighted the role of EZH2 in cell fate determination of MSC regulating adipogenic and osteogenic differentiation (Wang et al., 2010; Chen et al., 2011; Chen et al., 2016). However, it is not clear how the EZH2-mediated epigenetic silencing coordinates molecular events during differentiation. It was reported that the reciprocal action of EZH2 and KDM6A, which is an H3K27 demethylase, determines an epigenetic switch in MSC differentiation (Hemming et al., 2014). Wei and colleagues demonstrated that in human mesenchymal stem cells, CDK1 promotes mesenchymal stem cell differentiation into osteoblasts via phosphorylation of EZH2 at Thr 487 (Wei et al., 2010). We revealed that liganded-ERα facilitates H3K27 methylation on adipogenic target genes physically interacting with EZH2 in MSCs both in ovex and normal animals.
DNA methylation is a heritable modification that favours genomic integrity and ensures proper regulation of gene expression. It largely contributes to gene silencing (Zeng & Chen, 2019). We examined the DNA methylation status of PPARγ and C/EBPα upon estrogen administration. We have observed mosaicism in CpG methylation profile on adipogenic gene promoters between and within MSC clones similar to a previous study (Noer et al., 2006; Teven et al., 2011; Sinkkonen et al., 2008). Significantly higher DNA hypermethylation upon estrogen administration was only observed on C/EBPα in normal female-MSCs. On the contrary, there were no significant differences observed within ovex groups on C/EBPα and PPARγ.

In previous studies, the cross-talk between H3K27 methylation and DNA methylation was not demonstrated in stem cells. In normal cells, it is widely accepted that the genes which are repressed by EZH2 containing polycomb repressive complex 2 (PRC2), have mostly unmethylated CpG islands (Cedar & Bergman, 2009; Widschwendter et al., 2007). One possible explanation for this observation is that during gene silencing heterochromatinization is initiated by the polycomb repressive complexes. Subsequently, acquisition of DNA methylation occurs as a secondary event for long-term repression stability (Lande-Diner & Cedar, 2005). This was supported by a study which showed that de novo DNA methyltransferase three-like (Dnmt3L), which is a catalytically inactive DNA methyltransferase, interacts with the PRC2 complex in competition with the active DNA methyltransferases, Dnmt3a/3b. This maintains hypomethylation at the EZH2 and H3K27me3 positive promoters of the bivalent developmental genes in embryonic stem cells (Neri et al., 2013). Our bisulfite sequencing analyses were also demonstrated that estrogen has a role in the regulation of histone modifications, however, this interaction was not observed in DNA methylation in MSC. We concluded that estrogen reduces adipogenic gene transcription mainly acting on H3K27 methylation. This result also has been proved that in addition to methylation events, other epigenetic regulatory processes such as histone acetylation or recruitment of HMT complexes are also necessary to examine for the understanding underlining mechanism of differentiation of stem cells.

CONCLUSIONS
The signalling cross-talk between ERs and adipogenesis has been suggested in several studies. Our results may also bring an alternative explanation of how estrogen hormone and ERα inhibit adipogenesis in MSCs associated with epigenetic mediators. Our findings revealed that ERα induces enrichment of the H3K27 methylation on the promoters of master adipogenic transcription factor genes causing the inhibition of gene expression followed by attenuation of adipogenic differentiation in estrogen-dependent-manner in MSC. Estrogen may facilitate this methylation through modulating the interaction of ERα with EZH2 which is the H3K27 methyltransferase enzyme (Fig. 5). To date, only a few studies focusing on epigenetic regulation of MSC adipogenic differentiation have been conducted. An in-depth understanding of these mechanisms may provide findings to be easily translated into clinical practice given that the key role exerted by epigenetic deregulation in the development of obesity and determination of metabolic disorders has been widely acknowledged.
ACKNOWLEDGEMENTS

The experiments were carried out in the laboratories of İhsan Dogramaci Bilkent University Molecular Biology and Genetics Department and Ankara University Stem Cell Institute.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the Scientific and Technological Research Council of Turkey, TUBITAK (SBAG 109S460) and the Ankara University Scientific Research Projects (BAP) Coordination Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Scientific and Technological Research Council of Turkey, TUBITAK: SBAG 109S460. Ankara University Scientific Research Projects (BAP).

Competing Interests
The authors declare that they have no competing interests.

Author Contributions
- Ceylan V. Bitirim conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Zeynep B. Ozer conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Kamil C. Akcali conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Animal Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
Laboratory Animal Welfare and Ethics Committee of the Bilkent University approved this study (permission number: 2009/18).

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available as Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.12071#supplemental-information.
REFERENCES

Aaron N, Kraakman MJ, Zhou Q, Liu Q, Yang J, Liu L, Yu L, Wang L, He Y, Fan L, Hirakawa H, Ding L, Lo JC, Wang W, Zhao B, Edward Guo X, Sun I, Rosen CJ, Qiang L. 2021. Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells. bioRxiv DOI 10.1101/2021.04.13.439598.

Babaei P, Dastras A, Tehrani BS, Pourali Roudbaneh S. 2017. The effect of estrogen replacement therapy on visceral fat, serum glucose, lipid profiles and apelin level in ovariectomized rats. Journal of Menopausal Medicine 23(3):182 DOI 10.6118/jmm.2017.23.3.182.

Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. 1997. Effect of testosterone and estradiol in a man with aromatase deficiency. The New England Journal of Medicine 337(2):91–95 DOI 10.1056/NEJM199707103370204.

Cedar H, Bergman Y. 2009. Linking DNA methylation and histone modification: patterns and paradigms. Nature Reviews Genetics 10(5):295–304 DOI 10.1038/nrg2540.

Chen Y-H, Yeh F-L, Yeh S-P, Ma H-T, Hung S-C, Hung M-C, Li I-Y. 2011. Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by inactivating peroxisome proliferator-activated receptor γ-2. Journal of Biological Chemistry 286(12):10671–10680 DOI 10.1074/jbc.M110.199612.

Chen Q, Shou P, Zheng C, Jiang M, Cao G, Yang Q, Cao J, Xie N, Velletri T, Zhang X, Xu C, Zhang L, Yang H, Hou J, Wang Y, Shi Y. 2016. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death and Differentiation 23(7):1128–1139 DOI 10.1038/cdd.2015.168.

Chen YH, Chung CC, Liu YC, Yeh SP, Hsu JL, Hung MC, Su HL, Li LY. 2016. Enhancer of zeste homolog 2 and histone deacetylase 9c regulate age-dependent mesenchymal stem cell differentiation into osteoblasts and adipocytes. Stem Cells 34:2183–2193 DOI 10.1002/stem.2400.

Dang ZC, Löwik CWGM. 2004. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. Journal of Bone and Mineral Research 19:853–861 DOI 10.1359/jbmr.040120.

Evans RM, Barish GD, Wang Y-X. 2004. PPARs and the complex journey to obesity. Nature medicine 10:355–361 DOI 10.1038/nm1025.

Foryst-Ludwig A, Clemenz M, Hohmann S, Hartge M, Sprang C, Frost N, Krikov M, Bhanot S, Barros R, Morani A, Gustafsson J-A, Unger T, Kintscher U. 2008. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLOS Genetics 4:e1000108 DOI 10.1371/journal.pgen.1000108.

Glenske K, Schuler G, Arnhold S, Elashry MI, Wagner AS, Barbeck M, Neumann E, Müller-Ladner U, Schnettler R, Wenisch S. 2019. Effects of testosterone and 17β-estradiol on osteogenic and adipogenic differentiation capacity of human bone-derived mesenchymal stromal cells of postmenopausal women. Bone Reports 11(32):100226 DOI 10.1016/j.bonr.2019.100226.

Heim M, Frank O, Kampmann G, Sochocki N, Pennimpede T, Fuchs P, Hunziker W, Weber P, Martin I, Bendik I. 2004. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 145(2):848–859 DOI 10.1210/en.2003-1014.

Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. 2000. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proceedings of the National Academy of Sciences of the United States of America 97(23):12729–12734 DOI 10.1073/pnas.97.23.12729.
Hemming S, Cakouros D, Isenmann S, Cooper L, Menicanin D, Zannettino A, Gronthos S. 2014. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. *Stem Cells* 32(3):802–815 DOI 10.1002/stem.1573.

Hemming S, Cakouros D, Vandyke K, Davis MJ, Zannettino ACW, Gronthos S. 2016. Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. *Stem Cells and Development* 25(12):909–921 DOI 10.1089/scd.2015.0384.

Hong LIU, Colpan A, Peptan IA. 2006. Differentiation of human mesenchymal stem cells. 12:2747–2753 DOI 10.1089/ten.2006.12.2747.

Hong L, Zhang G, Sultana H, Yu Y, Wei Z. 2011. The effects of 17-β estradiol on enhancing proliferation of human bone marrow mesenchymal stromal cells in vitro. *Stem Cells and Development* 20(5):925–931 DOI 10.1089/scd.2010.0125.

Jeong S, Yoon M. 2007. Inhibition of the actions of peroxisome proliferator-activated receptor-alpha on obesity by estrogen. *Obesity (Silver Springer, MD)* 15(6):1430–1440 DOI 10.1038/oby.2007.171.

Jeong S, Yoon M. 2011. 17β-Estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression. *Acta Pharmacologica Sinica* 32(2):230–238 DOI 10.1038/aps.2010.198.

Kim BH, Won YS, Kim DY, Kim B, Kim EY, Yoon M, Oh GT. 2009. Signal crosstalk between estrogen and peroxisome proliferator-activated receptor alpha on adiposity. *BMB Reports* 42(2):91–95 DOI 10.5483/BMBRep.2009.42.2.091.

Lande-Diner L, Cedar H. 2005. Silence of the genes-mechanisms of long-term repression. *Nature Reviews Genetics* 6(8):648–654 DOI 10.1038/nrg1639.

Li L-C, Dahiya R. 2002. MethPrimer: designing primers for methylation PCRs. *Bioinformatics* (Oxford, England) 18:1427–1431 DOI 10.1093/bioinformatics/18.11.1427.

Li H, Xiao L, Wang C, Gao J, Zhai Y. 2010. Review: epigenetic regulation of adipocyte differentiation and adipogenesis. *Journal of Zhejiang University. Science. B* 11(10):784–791 DOI 10.1631/jzus.B0900401.

Ling C, Rönn T. 2019. Epigenetics in human obesity and type 2 diabetes. *Cell Metabolism* 29(5):1028–1044 DOI 10.1016/j.cmet.2019.03.009.

Liu K, Zou C, Qin B. 2017. The association between nuclear receptors and ocular diseases. *Oncotarget* 8(16):27603–27615 DOI 10.18632/oncotarget.15178.

Madsen MS, Siersbæk R, Boergesen M, Nielsen R, Mandrup S. 2014. Peroxisome proliferator-activated receptor γ and C/EBPα synergistically activate key metabolic adipocyte genes by assisted loading. *Molecular and Cellular Biology* 34(6):939–954 DOI 10.1128/MCB.01344-13.

Matsumura Y, Nakaki R, Inagaki T, Yoshida A, Kano Y, Kimura H. 2015. Targeted by lineage-specific DNA methylation pauses adipocyte differentiation article H3K4/H3K9me3 bivalent chromatin domains targeted by lineage-specific dna methylation pauses adipocyte differentiation. *Molecular Cell* 60(4):584–596 DOI 10.1016/j.molcel.2015.10.025.

Meyer MB, Benkusky NA, Sen B, Rubin J, Pike JW. 2016. Epigenetic plasticity drives adipogenic and osteogenic differentiation of marrow-derived mesenchymal stem cells. *Journal of Biological Chemistry* 291(34):17829–17847 DOI 10.1074/jbc.M116.736538.

Mu W, Starmer J, Yee D, Magnuson T. 2018. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation. *Epigenetics and Chromatin* 11(1):1–14 DOI 10.1186/s13072-018-0242-9.
Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R, Párrizas M. 2010. Histone demethylase LSD1 regulates adipogenesis. *The Journal of Biological Chemistry* 285(39):30034–30041 DOI 10.1074/jbc.M110.151209.

Noer A, Sorensen AL, Boquest AC, Collas P. 2006. Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. *Molecular Biology of the Cell* 17(8):3543–3556 DOI 10.1091/mbc.e06-04-0322.

Neri F, Incarnato D, Krepelova A, Rapelli S, Pagnani A, Zecchina R, Parlato C, Oliviero S. 2013. Genome-wide analysis identifies a functional association of Tet1 and Polycomb repressive complex 2 in mouse embryonic stem cells. *Genome Biology* 14(8):R91 DOI 10.1186/gb-2013-14-8-r91.

Okazaki RYO, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, Matsumoto T. 2002. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen. *Endocrinology* 143:2349–2356.

Palmisano BT, Zhu L, Stafford JM. 2017. Role of estrogens in the regulation of liver lipid metabolism. *Advances in Experimental Medicine and Biology* 1043:227–256 DOI 10.1007/978-3-319-70178-3_12.

Pedersen SB, Borglum JD, Møller-Pedersen T, Richelsen B. 1992. Effects of in vivo estrogen treatment on adipose tissue metabolism and nuclear estrogen receptor binding in isolated rat adipocytes. *Molecular and Cellular Endocrinology* 85(1–2):13–19 DOI 10.1016/0303-7207(92)90120-u.

Rosen ED, Hsu C, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM. 2002. C/EBPα induces adipogenesis through PPARγ: a unified pathway service C/EBPα induces adipogenesis through PPARγ: a unified pathway. *Research Communication* 16(1):22–26 DOI 10.1101/gad.948702.

Sävendahl L. 2005. Hormonal regulation of growth plate cartilage. *Hormone Research* 64(Suppl 2):94–97 DOI 10.1159/000087764.

Senyuk V, Sinha KK, Nucifora G. 2005. Corepressor CtBP1 interacts with and specifically inhibits CBP activity. *Archives of Biochemistry and Biophysics* 441:168–173 DOI 10.1016/j.abb.2005.06.024.

Shang Y, Hu X, Direnzo J, Lazar MA, Brown M, Endocrinology D. 2000. Cofactor dynamics and sufficiency in estrogen receptor–regulated transcription. *Cell* 103:843–852.

Stossi F, Madak-erdogan Z, Benita S. 2009. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. *Molecular and Cellular Biology* 29(7):1749–1759 DOI 10.1128/MCB.01476-08.

Stubbins RE, Holcomb VB, Hong J, Núñez NP. 2012. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. *European Journal of Nutrition* 51(7):861–870 DOI 10.1007/s00394-011-0266-4.

Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn M-Y, Takeyama K, Nakamura T, Mezaki Y, Takezawa S, Yogishi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S. 2007. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. *Nature Cell Biology* 9(11):1273–1285 DOI 10.1038/ncb1647.

Tang Q-Q, Zhang J-W, Daniel Lane M. 2004. Sequential gene promoter interactions of C/EBPβ, C/EBPα, and PPARγ during adipogenesis. *Biochemical and Biophysical Research Communications* 319(1):235–239 DOI 10.1016/j.bbrc.2004.04.176.
Teven CM, Liu X, Hu N, Tang N, Kim SH, Huang E, Yang K, Li M, Gao J-L, Liu H, Natale RB, Luther G, Luo Q, Wang L, Rames R, Bi Y, Luo J, Luu HH, Haydon RC, Reid RR, He T-C. 2011. Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation. Stem Cells International 2011:201371 DOI 10.4061/2011/201371.2011.

Wang L, Jin Q, Lee J-E, Su I, Ge K. 2010. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proceedings of the National Academy of Sciences of the United States of America 107(16):7317–7322 DOI 10.1073/pnas.100031107.

Wei Y, Chen Y-H, Li L-Y, Lang J, Yeh S-P, Shi B, Yang C-C, Yang J-Y, Lin C-Y, Lai C-C, Hung M-C. 2010. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nature Cell Biology 13(1):87–94 DOI 10.1038/ncb2139.

Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, Zavolan M, Svoboda P, Filipowicz W. 2008. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nature Structural and Molecular Biology 15(3):259–267 DOI 10.1038/nsmb.1391.

Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. 2007. Epigenetic stem cell signature in cancer. Nature Genetics 39(2):157–158 DOI 10.1038/ng1941.

Ye L, Fan Z, Yu B, Chang J, Al Hezaimi K, Zhou X, Park N-H, Wang C-Y. 2012. Histone demethylases KDM4B and KDM6B promote osteogenic differentiation of human MSCs. Cell Stem Cell 11(1):50–61 DOI 10.1016/j.stem.2012.04.009.

Zama AM, Uzumcu M. 2009. Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. Endocrinology 150(10):4681–4691 DOI 10.1210/en.2009-0499.

Zhang M, Chen F-M, Wang A-H, Chen Y-J, Lv X, Wu S, Zhao R-N. 2012. Estrogen and its receptor enhance mechanobiological effects in compressed bone mesenchymal stem cells. Cells, Tissues, Organs 195(5):400–413 DOI 10.1159/000328003.

Zhao J-W, Gao Z-L, Mei H, Li Y-L, Wang Y. 2011. Differentiation of human mesenchymal stem cells: the potential mechanism for estrogen-induced preferential osteoblast versus adipocyte differentiation. The American Journal of the Medical Sciences 341(6):460–468 DOI 10.1097/MAJ.0b013e31820865d5.

Zhou S, Zilberman Y, Wassermann K, Bain SD, Sadowsky Y, Gazit D. 2001. Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. Journal of Cellular Biochemistry 36(S36):144–155 DOI 10.1002/jcb.1096.

Zubaisty S, Oesterreich S. 2005. Estrogen-repressed genes–key mediators of estrogen action? Breast cancer research: BCR 7(4):163–164 DOI 10.1186/bcr1271.

Zuo Y, Qi, Li, Farmer SR. 2006. Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/EBP alpha gene promoter. The Journal of Biological Chemistry 281(12):7960–7967 DOI 10.1074/jbc.M510682200.